Hyundai Bioscience Co., Ltd. Share Price

Equities

A048410

KR7048410005

Personal Products

End-of-day quote Korea S.E. 03:30:00 30/04/2024 am IST 5-day change 1st Jan Change
20,250 KRW -0.25% Intraday chart for Hyundai Bioscience Co., Ltd. +0.25% -22.41%

Financials

Sales 2022 7.85B 5.76M 480M Sales 2023 9.48B 6.95M 580M Capitalization 1,039B 762M 63.51B
Net income 2022 -15.81B -11.59M -966M Net income 2023 -14.5B -10.63M -886M EV / Sales 2022 137 x
Net cash position 2022 12.48B 9.15M 763M Net cash position 2023 6.27B 4.59M 383M EV / Sales 2023 109 x
P/E ratio 2022
-68.2 x
P/E ratio 2023
-71.5 x
Employees 63
Yield 2022 *
-
Yield 2023
-
Free-Float 87.08%
More Fundamentals * Assessed data
Dynamic Chart
Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil CI
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer CI
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer CI
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection CI
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 32.47% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion. CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vector Inc. completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Vector Inc. agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. for KRW 13.7 billion. CI
Hyundai Bioscience to request a fast track processing for its monkeypox treatment drug with the FDA CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hyundai Bioscience Co., Ltd. Launches CP-COV03 Phase 2 Clinical Trials CI
More news
1 day-0.25%
1 week+0.25%
Current month-3.57%
1 month-3.57%
3 months-17.18%
6 months-47.61%
Current year-22.41%
More quotes
1 week
19 840.00
Extreme 19840
20 450.00
1 month
19 170.00
Extreme 19170
22 600.00
Current year
17 600.00
Extreme 17600
26 350.00
1 year
17 600.00
Extreme 17600
41 200.00
3 years
17 600.00
Extreme 17600
45 000.00
5 years
6 310.00
Extreme 6310
66 300.00
10 years
1 490.00
Extreme 1490
66 300.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 29/13/29
Chief Tech/Sci/R&D Officer 50 -
Director/Board Member 59 27/15/27
Members of the board TitleAgeSince
Chief Executive Officer 64 29/13/29
Director/Board Member 57 -
Director/Board Member 59 27/15/27
More insiders
Date Price Change Volume
02/24/02 19,990 -1.28% 243,087
30/24/30 20,250 -0.25% 154,692
29/24/29 20,300 +2.22% 211,771
26/24/26 19,860 -0.30% 186,471
25/24/25 19,920 -1.14% 178,589

End-of-day quote Korea S.E., April 30, 2024

More quotes
HYUNDAI BIOSCIENCE CO., LTD. it is a Korea-based company mainly engaged in the manufacturing and sale of bio cosmetics and hair tonic products. It develops functional daily necessities such as shampoos, mask packs, creams, and tumor-targeted drug. The Company also sells liquid crystal display (LCD) monitors and digital signage display products. The Company distributes its products in domestic market, as well as to the overseas markets, including Europe, America and Japan.
More about the company
  1. Stock Market
  2. Equities
  3. A048410 Stock